Increased expression of plasma hsa‐miR‐181a in male patients with heroin addiction use disorder

Xu, Wenjin; Zhao, Ming; Lin, Zhang; Liu, Haixiong; Ma, Hong; Hong, Qingxiao; Gui, Donghui; Feng, Jiying; Liu, Yue; Zhou, Wenhua; Liu, Huifen

doi:10.1002/jcla.23486

Cited by 11 publications

(8 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…PPI, protein-protein interaction. with the frequency of heroin-dependent and negatively correlated with the daily dosage in patients with heroin use disorder (33). However, in this study, the expression of miR-320 was positively correlated with MA daily use, which may be due to different illicit drugs generate different miRNAs expression profiles, and the specific dysregulated miRNAs molecules.…”

Section: Discussioncontrasting

confidence: 60%

“…Based on the above studies, we speculated that the dysfunction of miR-320 in plasma and exosomes could reflect the corresponding dysfunction in the brain caused by MA addiction. Previously, our group have found that the levels of miR-181a, miR-320a, and let-7b-5p in circulating plasma significantly increased in heroin-dependent patients, and demonstrated that these miRNAs can distinguish heroin addicts from healthy controls (22,33). Tobacco affects the central and circulating expression of miRNAs and is prevalent in drug-addicted patients (21,34).…”

Section: Discussionmentioning

confidence: 98%

See 1 more Smart Citation

Circulating plasma and exosome levels of the miR-320 family as a non-invasive biomarker for methamphetamine use disorder

Hong

Zhou

et al. 2023

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

The neurobiological mechanism underlying methamphetamine (MA) use disorder was still unclear, and no specific biomarker exists for clinical diagnosis of this disorder. Recent studies have demonstrated that microRNAs (miRNAs) are involved in the pathological process of MA addiction. The purpose of this study was to identify novel miRNAs for the diagnosis biomarkers of MA user disorder. First, members of the miR-320 family, including miR-320a-3p, miR-320b, and miR-320c, were screened and analyzed in the circulating plasma and exosomes by microarray and sequencing. Secondly, plasma miR-320 was quantified by real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) in eighty-two MA patients and fifty age-gender-matched healthy controls. Meanwhile, we also analyzed exosomal miR-320 expression in thirty-nine MA patients and twenty-one age-matched healthy controls. Furthermore, the diagnostic power was evaluated using the area under the curve (AUC) of the receiver operating characteristic (ROC) curve. The expression of miR-320 significantly increased in plasma and exosomes of MA patients compared with healthy controls. The AUC of the ROC curves of miR-320 in plasma and exosomes of MA patients were 0.751 and 0.962, respectively. And the sensitivities of miR-320 were 0.900 and 0.846, respectively, whereas the specificities of miR-320 were 0.537 and 0.952, respectively, in plasma and exosomes in MA patients. And the increased plasma miR-320 was positively correlated with cigarette smoking, age of onset, and daily use of MA in MA patients. Finally, cardiovascular disease, synaptic plasticity, and neuroinflammation were predicted to be the target pathways related to miR-320. Taken together, our findings indicated that plasma and exosomal miR-320 might be used as a potential blood-based biomarker for diagnosing MA use disorder.

show abstract

Section: Discussioncontrasting

confidence: 60%

Section: Discussionmentioning

confidence: 98%

Circulating plasma and exosome levels of the miR-320 family as a non-invasive biomarker for methamphetamine use disorder

Hong

Zhou

et al. 2023

Front. Psychiatry

Self Cite

View full text Add to dashboard Cite

show abstract

“…Some known biological roles for let-7b, which was the first defined human miRNA, include the regulation of stem-cell differentiation, cell differentiation, and neuromuscular development. Many studies have shown that let-7b has putative target sites on several addiction-related genes and causes neurodegeneration diseases 17 . The findings of our study highlight a new role of let-7b-3p in methamphetamine-seeking behavior.…”

Section: Introductionmentioning

confidence: 99%

Evaluation of microRNA let-7b-3p expression levels in methamphetamine abuse

Demirel

Tanoglu

Aslıyüksek

2023

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

OBJECTIVE:In this study, we aimed to identify a microRNA expression signature that could be used to distinguish methamphetamine from control samples. We also utilized the existing bioinformatics tools in order to predict the candidate microRNAs that could play potential key roles in regulating drug addiction-related genes. METHODS: Methamphetamine samples from 21 ventral tegmental area and 21 nucleus accumbens samples and their control regions were obtained from the Council of Forensic Medicine (Istanbul). Quantitative analysis of let-7b-3p was studied using quantitative reverse transcription PCR. Statistical analysis was carried out using Student's t-test. The receiver operating characteristic curves were plotted with Statistical Package for the Social Sciences (SPSS 20.0). RESULTS: Our quantitative reverse transcription PCR results revealed that let-7b-3p was significantly overexpressed in brain tissues of the methamphetamine-user group. Let-7b-3p had significant power to discriminate methamphetamine from control samples in the ventral tegmental area (AUC; 0.922) and nucleus accumbens (AUC; 0.899) regions. CONCLUSION: We have shown for the first time in the literature the differential expression of let-7b-3p in samples from methamphetamineaddicted individuals. We suggest that let-7b-3p could be a powerful marker for the diagnosis of methamphetamine addiction. Our results showed that differentially expressed let-7b-3p in methamphetamine users could be used as a diagnostic and therapeutic marker.

show abstract

“…In particular, miR-212, miR-132, miR-181, miR-9, and let-7 may be of interest for clinical targeting as altered expression of these miRs has been observed across multiple drugs of abuse in human and animal samples ( 14 ). In addition to miR activity in the brain, miR levels in SUD patient blood samples have been correlated with drug history and relapse ( 23 , 85 – 94 ). Thus, circulating miRs may be a useful auxiliary measurement for diagnosis and treatment.…”

Section: Introductionmentioning

confidence: 99%

Noncoding RNA therapeutics for substance use disorder

Seyednejad

Sartor

2022

Adv. Drug Alcohol Res.

View full text Add to dashboard Cite

Although noncoding RNAs (ncRNAs) have been shown to regulate maladaptive neuroadaptations that drive compulsive drug use, ncRNA-targeting therapeutics for substance use disorder (SUD) have yet to be clinically tested. Recent advances in RNA-based drugs have improved many therapeutic issues related to immune response, specificity, and delivery, leading to multiple successful clinical trials for other diseases. As the need for safe and effective treatments for SUD continues to grow, novel nucleic acid-based therapeutics represent an appealing approach to target ncRNA mechanisms in SUD. Here, we review ncRNA processes implicated in SUD, discuss recent therapeutic approaches for targeting ncRNAs, and highlight potential opportunities and challenges of ncRNA-targeting therapeutics for SUD.

show abstract

Increased expression of plasma hsa‐miR‐181a in male patients with heroin addiction use disorder

Abstract: This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Cited by 11 publications

References 57 publications

Circulating plasma and exosome levels of the miR-320 family as a non-invasive biomarker for methamphetamine use disorder

Circulating plasma and exosome levels of the miR-320 family as a non-invasive biomarker for methamphetamine use disorder

Evaluation of microRNA let-7b-3p expression levels in methamphetamine abuse

Noncoding RNA therapeutics for substance use disorder

Contact Info

Product

Resources

About